These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28317644)

  • 21. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Ten Kate M; Barkhof F; Boccardi M; Visser PJ; Jack CR; Lovblad KO; Frisoni GB; Scheltens P;
    Neurobiol Aging; 2017 Apr; 52():167-182.e1. PubMed ID: 28317647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist.
    Budson AE; Solomon PR
    Pract Neurol; 2012 Apr; 12(2):88-96. PubMed ID: 22450454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
    Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
    Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subjective Cognitive Decline in Preclinical Alzheimer's Disease.
    Rabin LA; Smart CM; Amariglio RE
    Annu Rev Clin Psychol; 2017 May; 13():369-396. PubMed ID: 28482688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments.
    Garrett MD; Valle R
    Dementia (London); 2016 Mar; 15(2):239-54. PubMed ID: 24662500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
    Frisoni GB; Boccardi M; Barkhof F; Blennow K; Cappa S; Chiotis K; Démonet JF; Garibotto V; Giannakopoulos P; Gietl A; Hansson O; Herholz K; Jack CR; Nobili F; Nordberg A; Snyder HM; Ten Kate M; Varrone A; Albanese E; Becker S; Bossuyt P; Carrillo MC; Cerami C; Dubois B; Gallo V; Giacobini E; Gold G; Hurst S; Lönneborg A; Lovblad KO; Mattsson N; Molinuevo JL; Monsch AU; Mosimann U; Padovani A; Picco A; Porteri C; Ratib O; Saint-Aubert L; Scerri C; Scheltens P; Schott JM; Sonni I; Teipel S; Vineis P; Visser PJ; Yasui Y; Winblad B
    Lancet Neurol; 2017 Aug; 16(8):661-676. PubMed ID: 28721928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renovating Alzheimer's: "constructive" reflections on the new clinical and research diagnostic guidelines.
    George DR; Qualls SH; Camp CJ; Whitehouse PJ
    Gerontologist; 2013 Jun; 53(3):378-87. PubMed ID: 22936533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer's Dementia? : Applying the Method of Reflective Equilibrium for a Clinical Dilemma.
    Smedinga M; Bunnik EM; Richard E; Schermer MHN
    J Bioeth Inq; 2022 Jun; 19(2):287-297. PubMed ID: 35306635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biomarkers in Alzheimer's disease].
    García-Ribas G; López-Sendón Moreno JL; García-Caldentey J
    Rev Neurol; 2014 Apr; 58(7):308-17. PubMed ID: 24677154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology.
    Boccardi M; Gallo V; Yasui Y; Vineis P; Padovani A; Mosimann U; Giannakopoulos P; Gold G; Dubois B; Jack CR; Winblad B; Frisoni GB; Albanese E;
    Neurobiol Aging; 2017 Apr; 52():141-152. PubMed ID: 28317645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.